Timothy Clackson

Direktor/Vorstandsmitglied bei ELEVATION ONCOLOGY, INC.

Vermögen: 172 518 $ am 30.04.2024

58 Jahre

100 Beziehungen

Health Technology

Consumer Services

Commercial Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Ben Auspitz	M	-	IDRx, Inc. IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.	-
Joseph Ferra	M	49	ELEVATION ONCOLOGY, INC.	3 Jahre
Steven Elms	M	60	ELEVATION ONCOLOGY, INC.	5 Jahre
Candice Masse	F	-	ELEVATION ONCOLOGY, INC.	-
Robert M. Forrester	M	60	IDRx, Inc. IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.	-
Ulrich Christian Otte	M	-	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre
Darcy Mootz	M	-	ELEVATION ONCOLOGY, INC.	-
R. Carruthers	M	66	ELEVATION ONCOLOGY, INC.	3 Jahre
Tammy Furlong	F	-	ELEVATION ONCOLOGY, INC.	-
Jeannette Potts	M	62	FORMA THERAPEUTICS HOLDINGS, INC.	5 Jahre
David Dornan	M	46	ELEVATION ONCOLOGY, INC.	2 Jahre
Robert Yang	M	-	ELEVATION ONCOLOGY, INC.	-
Steve Benz	M	-	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre
Ifeyinwa Osunkwo	M	-	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre
Valerie Jansen	M	46	ELEVATION ONCOLOGY, INC.	-
David N. Cook	M	66	FORMA THERAPEUTICS HOLDINGS, INC.	4 Jahre
Ruth du Moulin	F	-	FORMA THERAPEUTICS HOLDINGS, INC.	4 Jahre
Kristine Callahan	F	-	THESEUS PHARMACEUTICALS, INC.	3 Jahre
Christoph S. Lengauer	M	59	IDRx, Inc. IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.	-
Todd Shegog	M	59	FORMA THERAPEUTICS HOLDINGS, INC.	5 Jahre
Jorge Conde	M	47	IDRx, Inc. IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.	-
Eli Casdin	M	51	IDRx, Inc. IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.	-
Mario Corso	M	-	FORMA THERAPEUTICS HOLDINGS, INC.	4 Jahre
Thomas Haagen	M	58	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Shawn Leland	M	40	ELEVATION ONCOLOGY, INC.	4 Jahre
Harvey J. Berger	M	74	ARIAD PHARMACEUTICALS, INC.	24 Jahre
Maria E. Cantor	F	56	ARIAD PHARMACEUTICALS, INC.	-
William Shakespeare	M	60	ARIAD PHARMACEUTICALS, INC. THESEUS PHARMACEUTICALS, INC.	27 Jahre
Alexander Denner	M	54	ARIAD PHARMACEUTICALS, INC.	3 Jahre
Michael A. Foley	M	62	FORMA THERAPEUTICS HOLDINGS, INC.	9 Jahre
Thomas DesRosier	M	69	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Frank Lee	M	56	FORMA THERAPEUTICS HOLDINGS, INC.	3 Jahre
Pierre F. Dodion	M	69	ARIAD PHARMACEUTICALS, INC.	-
Raymond T. Keane	M	65	ARIAD PHARMACEUTICALS, INC.	5 Jahre
Paris Panayiotopoulos	M	50	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Peter Kolchinsky	M	47	FORMA THERAPEUTICS HOLDINGS, INC.	3 Jahre
Massimo Radaelli	M	65	ARIAD PHARMACEUTICALS, INC.	8 Jahre
Kelly M. Schmitz	M	-	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Selwyn Vickers	M	64	FORMA THERAPEUTICS HOLDINGS, INC.	1 Jahre
Elona Kogan	F	54	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Edward Fitzgerald	M	68	ARIAD PHARMACEUTICALS, INC.	14 Jahre
Paolo Augusto Paoletti	M	73	FORMA THERAPEUTICS HOLDINGS, INC.	6 Jahre
Wayne Frederick	M	52	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre
Steve Hall	M	69	FORMA THERAPEUTICS HOLDINGS, INC.	11 Jahre
Michal Silverberg	F	48	FORMA THERAPEUTICS HOLDINGS, INC.	3 Jahre
Yan Moore	M	58	ARIAD PHARMACEUTICALS, INC.	2 Jahre
Steven Stein	M	57	THESEUS PHARMACEUTICALS, INC.	2 Jahre
Kathy Yi	F	52	THESEUS PHARMACEUTICALS, INC.	3 Jahre
Sergio Santillana	M	61	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Lori Hu	F	38	ELEVATION ONCOLOGY, INC.	5 Jahre
David Kerstein	M	41	ARIAD PHARMACEUTICALS, INC. THESEUS PHARMACEUTICALS, INC.	7 Jahre
Colin Walsh	M	38	ELEVATION ONCOLOGY, INC.	4 Jahre
Patrick F. Kelly	M	60	FORMA THERAPEUTICS HOLDINGS, INC.	6 Jahre
Robert Whelan	M	72	ARIAD PHARMACEUTICALS, INC.	4 Jahre
Matthew Ros	M	57	ARIAD PHARMACEUTICALS, INC.	3 Jahre
Wayne L. Wilson	M	75	ARIAD PHARMACEUTICALS, INC.	8 Jahre
Daniel M. Bollag	M	63	ARIAD PHARMACEUTICALS, INC.	8 Jahre
Peter Wirth	M	73	FORMA THERAPEUTICS HOLDINGS, INC.	10 Jahre
Laurie A. Allen	F	63	ARIAD PHARMACEUTICALS, INC.	9 Jahre
Christophe M. Bianchi	M	62	ARIAD PHARMACEUTICALS, INC.	-
Norbert Riedel	M	66	ARIAD PHARMACEUTICALS, INC.	6 Jahre
David L. Berstein	M	72	ARIAD PHARMACEUTICALS, INC.	14 Jahre
Sarah Schlesinger	M	64	ARIAD PHARMACEUTICALS, INC.	4 Jahre
Manmeet Singh Soni	M	46	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Donald Hayden	M	68	THESEUS PHARMACEUTICALS, INC.	2 Jahre
Thomas Wiggans	M	72	FORMA THERAPEUTICS HOLDINGS, INC.	2 Jahre
Athanase Lavidas	M	75	ARIAD PHARMACEUTICALS, INC.	13 Jahre
Arturo Molina	M	65	FORMA THERAPEUTICS HOLDINGS, INC.	-
George Bickerstaff	M	68	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Marsha Fanucci	F	70	FORMA THERAPEUTICS HOLDINGS, INC.	8 Jahre
Lee C. Steele	M	75	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Anna Protopapas	F	59	ARIAD PHARMACEUTICALS, INC.	2 Jahre
Jules Haimovitz	M	73	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Jay R. LaMarche	M	76	ARIAD PHARMACEUTICALS, INC.	24 Jahre
Richard Gaster	M	40	ELEVATION ONCOLOGY, INC.	2 Jahre
Melanie Morel-Ferris	F	44	ARIAD PHARMACEUTICALS, INC.	-
Andrew Phillips	M	53	ELEVATION ONCOLOGY, INC.	1 Jahre
Paul Sekhri	M	65	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Victor Rivera	M	59	ARIAD PHARMACEUTICALS, INC.	24 Jahre
Jayne M. Gansler	F	-	ARIAD PHARMACEUTICALS, INC.	-
Matthew P. Kowalsky	M	52	ARIAD PHARMACEUTICALS, INC.	-
Mark Organisak	M	-	ARIAD PHARMACEUTICALS, INC.	2 Jahre
Jing Marantz	M	59	ARIAD PHARMACEUTICALS, INC.	-
Piet A. M. Vervaet	M	-	ARIAD PHARMACEUTICALS, INC.	-
Joseph Bratica	M	60	ARIAD PHARMACEUTICALS, INC.	22 Jahre
Jane F. Amara	M	-	ARIAD PHARMACEUTICALS, INC.	7 Jahre
Virginia R. Dean	F	58	ARIAD PHARMACEUTICALS, INC.	-
Ross Pettit	M	-	ARIAD PHARMACEUTICALS, INC.	-
Mary C. Tanner	F	73	ARIAD PHARMACEUTICALS, INC.	-
Keith Regnante	M	54	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Maryann G. Krane	F	64	ARIAD PHARMACEUTICALS, INC.	-
Tao Guo	M	-	ARIAD PHARMACEUTICALS, INC.	3 Jahre
Hugh Cole	M	59	ARIAD PHARMACEUTICALS, INC.	3 Jahre
Michael Kishbauch	M	75	ARIAD PHARMACEUTICALS, INC.	4 Jahre
Andreas Woppmann	M	-	ARIAD PHARMACEUTICALS, INC.	-
John McCabe	M	55	ARIAD PHARMACEUTICALS, INC.	1 Jahre
Sandy Smith	M	77	ARIAD PHARMACEUTICALS, INC.	17 Jahre
Stephen R. Jamieson	M	-	ARIAD PHARMACEUTICALS, INC.	-
Liza Heapes	F	-	ARIAD PHARMACEUTICALS, INC.	-
Alicja Januszewicz	M	-	THESEUS PHARMACEUTICALS, INC.	1 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Vereinigte Staaten	100	100,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Timothy Clackson
Persönliches Netzwerk